Overexpression of LIM and SH3 protein 1 leading to accelerated G2/M phase transition contributes to enhanced tumourigenesis in oral cancer

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Shimizu, Fumie ^a   Shiiba, Masashi ^a   Ogawara, Katsunori ^a,b   Kimura, Ryota ^a   Minakawa, Yasuyuki ^a   Baba, Takao ^a   Yokota, Satoshi ^a   Nakashima, Dai ^a   Higo, Morihiro ^b   Kasamatsu, Atsushi ^b   Sakamoto, Yosuke ^b   Tanzawa, Hideki ^a   Uzawa, Katsuhiro ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIM AND SH3 PROTEIN 1; LIM PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOGENESIS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; G2 PHASE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIM DOMAIN PROTEINS; MOUTH NEOPLASMS; RNA, MESSENGER; UP-REGULATION;

EID: 84891294738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083187     Document Type: Article

References (38)

1. Kudo Y, Takata T, Yasui W, Ogawa I, Miyauchi M, et al. (1998) Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma. Cancer 83: 2447-2455 (Pubitemid 29019562)
2. Hsu LC, Huang X, Seasholtz S, Potter DM, Gollin SM (2006) Gene amplification and overexpression of protein phosphatase 1alpha in oral squamous cell carcinoma cell lines. Oncogene 25: 5517-5526 (Pubitemid 44344102)
3. Shao Y, Qu Y, Dang S, Yao B, Ji M (2013) MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int 13: 51
4. Shi Y, Ding X, He ZH, Zhou KC, Wang Q, et al. (2009) Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut 58: 1443-1450
5. Schultz J, Ibrahim SM, Vera J, Kunz M (2009) 14-3-3sigma gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. Mol Cancer 8: 53
6. Ignatov T, Modl S, Thulig M, Weibenborn C, Treeck O, et al. (2013) GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res 6: 51
7. Frietsch JJ, Grunewald TG, Jasper S, Kammerer U, Herterich S, et al. (2010) Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer. Br J Cancer 102: 1645-1653
8. Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P, et al. (1995) Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett 373: 245-249
9. Lin YH, Park ZY, Lin D, Brahmbhatt AA, Rio MC, et al. (2004) Regulation of cell migration and survival by focal adhesion targeting of Lasp-1. J Cell Biol 165: 421-432 (Pubitemid 38649916)
10. Chew CS, Parente JA, Zhou C, Baranco E, Chen X (1998) Lasp-1 is a regulated phosphoprotein within the cAMP signaling pathway in the gastric parietal cell. Am J Physiol 275: C56-67
11. Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, et al. (2006) Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 312: 974-982
12. Zhao L, Wang H, Liu C, Liu Y, Wang X, et al. (2010) Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut 59: 1226-1235
13. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, et al. (2007) Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 96: 296-305 (Pubitemid 46160635)
14. Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, et al. (2012) Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol 30: 434-443
15. Traenka C, Remke M, Korshunov A, Bender S, Hielscher T, et al. (2010) Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 70: 8003-8014
16. Wang H, Li W, Jin X, Cui S, Zhao L (2013) LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer 49: 974-983
17. Hirota T, Morisaki T, Nishiyama Y, Marumoto T, Tada K, et al. (2000) Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J Cell Biol 149: 1073-1086 (Pubitemid 30354257)
18. Nix DA, Fradelizi J, Bockholt S, Menichi B, Louvard D, et al. (2001) Targeting of zyxin to sites of actin membrane interaction and to the nucleus. J Biol Chem 276: 34759-34767
19. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, et al. (2005) Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16: 269-273
20. Endo Y, Uzawa K, Mochida Y, Shiiba M, Bukawa H, et al. (2004) Sarcoendoplasmic reticulum Ca(2+) ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer 110: 225-231 (Pubitemid 38580395)
21. Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, et al. (2005) Aberrant expression of RAB1A in human tongue cancer. Br J Cancer 92: 1915-1921 (Pubitemid 40826141)
22. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, et al. (1999) Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 59: 5724-5731
23. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, et al. (2006) Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 94: 717-723 (Pubitemid 43361904)
24. Verburg FA, Wä schle K, Reiners C, Giovanella L, Lentjes EG (2010) Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res 42: 736-739
25. D?az-Rodr?guez E, A lvarez-Fernandez S, Chen X, Paiva B, Lopez-Perez R, et al. (2011) Deficient spindle assembly checkpoint in multiple myeloma. PLoS One 6: e27583
26. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815 (Pubitemid 32458690)
27. Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486
28. Collins I, Garrett MD (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5: 366-373 (Pubitemid 40932038)
29. Pines J, Hunter T (1989) Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 58: 833-846 (Pubitemid 19227894)
30. Yam CH, Fung TK, Poon RY (2002) Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 59: 1317-1326
31. Shubbar E, Kovacs A, Hajizadeh S, Parris TZ, Nemes S, et al. (2013) Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer 13: 1
32. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992) Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971
33. Sun M, Mo W, Fu X, Wu G, Huang Y, et al. (2010) System biology analysis of cell cycle pathway involved in hepatocellular carcinoma. Front Biosci (Schol Ed) 2: 1127-1144
34. Parker LL, Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257: 1955-1957
35. Ruiz EJ, Vilar M, Nebreda AR (2010) A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. Curr Biol 20: 717-723
36. Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344: 503-508
37. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW (1991) cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67: 197-211 (Pubitemid 121001436)
38. Coleman TR, Dunphy WG (1994) Cdc2 regulatory factors. Curr Opin Cell Biol 6: 877-882 (Pubitemid 24357921)